Human Genome Sciences, Inc. was founded in 1992 and is headquartered in Rockville, Maryland. Human Genome Sciences, Inc. operates as a biopharmaceutical company in the United States. The company's clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, and cancer. It focuses on the commercialization of Albuferon (albinterferon alfa-2b) for hepatitis C and LymphoStat-B (belimumab) for lupus. The company has completed Phase III development trials for Albuferon and is conducting two Phase III clinical trials of LymphoStat-B. It also delivers doses of ABthrax (raxibacumab) to the U.S. Strategic National Stockpile for use in the event of an emergency for the treatment of inhalation anthrax. In addition, the company has various drugs in the earlier stages of clinical development for the treatment of cancer, led by the TRAIL receptor antibody HGS-ETR1 and a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins. Further, Human Genome Sciences, Inc., through a strategic collaboration agreement with GlaxoSmithKline, has substantial financial rights to certain products in the GlaxoSmithKline clinical pipeline, including darapladib that is in Phase III development as a treatment for coronary heart disease; and Syncria (albiglutide), which is in Phase III development as a treatment for type 2 diabetes. Additionally, it has a strategic commercial collaboration agreement with Novartis International Pharmaceutical, Ltd. for the co-development and commercialization of Albuferon; and a strategic licensing and collaboration agreement with Aegera Therapeutics, Inc. to develop and commercialize HGS1029 and other small-molecule inhibitors of IAP (inhibitor of apoptosis) proteins in oncology.

SurModics, Inc. Company was founded in 1979 and is headquartered in Eden Prairie, Minnesota. SurModics, Inc. engages in the development, manufacture, and sale of surface modification and drug delivery technologies to the healthcare industry. The company operates through four business units: Cardiovascular, Ophthalmology, SurModics Pharmaceuticals, and In Vitro Technologies. The Cardiovascular business unit supports the drug delivery and surface modification needs of cardiovascular customers by providing drug delivery polymers and coating technologies, including advanced lubricity (slippery) coatings that ease placement and maneuverability of medical devices in the body. The Ophthalmology business unit develops drug delivery systems for various drugs and other bioactive agents developed by pharmaceutical and ophthalmology companies for the treatment of serious eye diseases.The SurModics Pharmaceuticals business unit specializes in proprietary injectable microparticles and implants based on biodegradable polymers to provide sustained delivery of drugs, as well as supplies biodegradable polymers to corporate and academic customers. The In Vitro Technologies business unit specializes in in vitro diagnostic products and technologies for the biomedical research and medical diagnostic markets. Its products and technologies include protein stabilization reagents, substrates, recombinant autoimmune antigens, surface chemistry technologies for nucleic acid and protein immobilization, and diagnostic format intellectual property. The company markets its technologies and products through sales professionals, as well as sales and marketing relationships with third-parties worldwide. It has collaboration agreements with Genzyme Corporation to develop novel drug delivery solutions with an initial focus on peptide delivery.

The Westaim Corporation was founded in 1996. The Westaim Corporation, a holding company, develops, manufactures and commercializes medical products that fight infection and inflammation. Nucryst Pharmaceuticals Corp. Nucryst develops, manufactures and commercializes innovative medical products that fight infection and inflammation. Wound Care Products: Acticoat Burn Dressings and Acticoat 7 Dressings, targeting the burn and chronic wound markets, were developed and sold by Nucryst. Nucryst's license to Smith & Nephew grants Smith & Nephew the exclusive worldwide right to market, distribute and sell Acticoat products using Nucryst's SILCRYST coatings for use on non-minor dermal wounds or burns in humans, including improvements to those products, and any new products developed with Smith & Nephew using Nucryst's SILCRYST coatings or powders in the Field. There are six product families with SILCRYST coatings manufactured by Nucryst for Smith & Nephew at its Fort Saskatchewan plant: Acticoat Burn, Acticoat 7, Acticoat Absorbent, Acticoat Moisture Control, Acticoat Site, and Acticoat Post-Op. In 2008, Nucryst announced that Health Canada granted marketing approval for a new SILCRYST product, Acticoat Flex Barrier Dressing. Agreements with Smith & Nephew: In 2007, Nucryst signed amended agreements with Smith & Nephew for the manufacture and sale of Acticoat products.

Nutrition 21, Inc. company was founded in 1983 and is headquartered in Purchase, New York. Nutrition 21, Inc., a nutritional bioscience company, develops, markets, and distributes proprietary and clinically substantiated nutritional supplements in the United States. The company sells Chromax branded chromium picolinate to vitamin and supplement and food manufacturers and marketers, as well as directly to retailers for use in human and animal nutrition products. It also develops and commercializes Diabetes Essentials, a proprietary, non-prescription, insulin sensitizer for people with type 2 diabetes. In addition, the company offers a portfolio of health and wellness products under the Iceland Health Maximum Strength Omega-3, Iceland Health Joint Relief, Iceland Health Advanced Memory Formula, Chromax chromium picolinate, Prescriptix Supplements, and Diabetes Essentials names. In addition, Nutrition 21, Inc. grants patent licenses to its ingredients to manufacturers and marketers of vitamin and mineral supplements.

Caprius, Inc. company owns a majority interest in MCM Environmental Technologies, which provides systems for disposal of medical waste. Its SteriMed system can crush, grind, shred, and mix all types of medical waste, including metal sharps and needles, plastic tubing and IV bags, and glass items. Once this process is complete, MCM's Steri-Cid chemical process disinfects the waste, which can then be discarded as regular waste at as little as 10% of the original volume. MCM manufactures the SteriMed system in Israel; the company distributes parts and supplies from facilities in Israel. Officers and directors, led by Austin W. Marxe and David M. Greenhouse hold about 22% of Caprius.

AVEO Pharmaceuticals' models don't pout, strut, or even turn heads -- unless you're a cancer drug researcher. The biotech firm develops cancer models to uncover how genes mutate into tumors and how tumors progress through additional mutations. AVEO then builds genetic profiles of such tumors and applies them to antibody (protein) drug candidates in preclinical and clinical development to help predict actual human responses. In addition to its own pipeline of potential drugs, AVEO has partnered with other pharmaceutical developers to apply its Human Response Platform to their drug candidates.

Aspen Pharmacare Holdings is the holding company of Aspen Pharmacare. The company is Africa's largest generic pharmaceutical manufacturer and a major supplier of branded pharmaceutical and healthcare products to southern African and some other international markets. Its products include pain medication, vitamins, cough and cold medicines, laxatives, medicine for indigestion, and aids to help people quit smoking and lose weight. Aspen Pharmacare also led the way in developing the first anti-retroviral medication in South Africa for AIDS treatment. Aspen Pharmacare Holdings Ltd. company has manufacturing facilities in Africa, India, and Latin America.

Dendreon Corporation, formerly known as Activated Cell Therapy, Inc., was founded in 1992 and is headquartered in Seattle, Washington. Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that improve cancer treatment options for patients. Dendreon’s most advanced product candidate is Provenge (sipuleucel-T), an active cellular immunotherapy that has completed two Phase III trials for the treatment of asymptomatic, metastatic, androgen-independent prostate cancer.

Raptor Pharmaceuticals Corp was founded in 2005 and is based in Novato, California. Raptor Pharmaceuticals Corp. operates as a development stage biotechnology company in the United States. The company engages in the discovery, research, and preclinical development of drug candidates and drug-targeting platforms for the treatment of various brain disorders and neurodegenerative diseases, genetic disorders, and cancer through the proprietary use of receptor-associated proteins and mesoderm development proteins. Its clinical-stage products include DR Cysteamine, which is in Phase IIb clinical trail for the treatment of nephropathic cystinosis or cystinosis; and in Phase IIa clinical trail for the treatment of non-alcoholic steatohepatitis. The company also develops Convivia, a Phase IIa clinical trail product for the treatment of aldehyde dehydrogenase or ALDH2 deficiency; DR Cysteamine, which is in Phase II clinical trail for the treatment of Huntington’s Disease; and Tezampanel and NGX 426 that is in Phase II clinical trail for the treatment of migraine, acute pain, and chronic pain. In addition, its preclinical development products comprise HepTide for the treatment of Hepatocellular Carcinoma and Hepatitis C; WntTide for the treatment of breast cancer; and NeuroTrans for the treatment of neurodegenerative diseases. The company has collaboration agreements with the University of California, San Diego for a clinical study of DR Cysteamine in juvenile patients with Non-Alcoholic Steatohepatitis and to study DR Cysteamine in patients with cystinosis.

Icagen, Inc. company was founded in 1992 and is based in Durham, North Carolina. Icagen, Inc. (Icagen) is a biopharmaceutical company focused on the discovery, development and commercialization of orally-administered small molecule drugs that modulate ion channel targets. The Company’s programs include ICA-105665 for epilepsy and neuropathic pain, for which the Company is conducting a Phase I multiple ascending dose study in healthy volunteers and epilepsy patients and Senicapoc, previously referred to as ICA-17043, for asthma, for which the Company is conducting two Phase II proof-of-concept clinical trials.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.